Bill > S1041

This bill, titled the Affordable Prescriptions for Patients Act, aims to clarify and modify patent infringement rules specifically for biological products, which are complex medicines often derived from living organisms. It amends existing law to ensure that when a company seeks approval for a biosimilar (a less expensive, highly similar version of an existing biological product, referred to as a "subsection (k) applicant" in relation to the Public Health Service Act), the original manufacturer (the "reference product sponsor") can assert patents that cover the biological product itself, its uses, or the methods and products used to manufacture it. The bill introduces a limit, generally allowing the reference product sponsor to assert a maximum of 20 patents in an infringement lawsuit against a biosimilar applicant, with specific restrictions on how many of those patents can have been issued after a certain date. However, this limit can be increased by a court if certain conditions are met, such as the biosimilar applicant failing to provide necessary information or if there's a significant change to the biosimilar product or its manufacturing process, or if there was a delay in the patent issuance. The bill also clarifies that this patent limitation does not apply to patents claiming a method of using the biological product for therapy, diagnosis, or prophylaxis. These changes are intended to streamline the patent litigation process for biosimilars, potentially making them more accessible to patients.